# PHARMACODYNAMICS

# MECHANISMS OF DRUG ACTION



# PROF. HANAN HAGAR

#### ILOS

➤ Identify different targets of drug action

Differentiate between their patterns of action; agonism versus antagonism

Elaborate on drug binding to receptors




### WHAT IS PHARMACODYNAMICS?

**Pharmacodynamics** is a branch of pharmacology that deals with the study of the biochemical and physiological effects of drugs and their mechanisms of action.

## WHAT ARE THE MECHANISMS OF DRUG ACTION?

# How drugs produce action? What are targets for drug binding?



### WHAT ARE THE MECHANISMS OF DRUG ACTION?

# Drugs can produce their actions by one of the following mechanisms:

- 1) Receptor-mediated mechanisms (Binding with biomolecules):
  - Receptors = Biomolecules = Targets
  - Targets are mostly <u>protein in nature</u>.
- Non receptor-mediated mechanisms
   Physiochemical properties of drugs.

# Non receptor—mediated mechanisms Drugs can produce actions by:

#### **Chemical action**

- Neutralization of gastric acidity by antacids.

#### Physical action


- Osmotic diuretics.
- Purgatives used in treatment of constipation e.g.
   MgSO4

### Receptor-mediated mechanisms

# Drugs can produce actions by binding with biomolecules (Protein Targets)

#### Protein targets for drug binding

- Structural protein
- Regulatory proteins
  - Physiological receptors
  - Enzymes
  - Ion channels
  - Carriers



#### Receptors


Is a special target macromolecule that binds the drug and mediates its pharmacological actions.


#### Where are receptors located?

- Cell membrane.
- Cytoplasm.
- Nucleus.

#### **Enzymes**

- The drug competes with the natural endogenous substrate for the enzyme.
- E.g. Anticholinesterases inhibit acetylcholinesterase thus producing cholinomimetic action.
- Neostigmine reversibly compete with ACH for acetyl cholinesterase enzyme at motor end plate (neuromuscular junction).
- Organophosphates irreversibly competes with ACH for acetyl cholinesterase enzyme.





#### Ion channels

- Drugs bind to alter channel function (by opening or blockade).
- Channels are responsible for influx or outflux of ions through cell membranes.
- They are activated by alteration in action potential.

#### Ion channels

#### e.g. local anesthetics:


act by blocking sodium (Na+) influx through Na channel in nerve fibers (Na channel blockers).



**REGULATORY** 

### ION CHANNEL


Local Anesthetics block Na influx through Na channel in nerve fibers. They are Na channel Blockers.



#### Ion channels

• e.g. Sulfonylurea drugs (antidiabetic drugs):

block potassium channels in pancreatic beta cells resulting in depolarization and opening of calcium channels and insulin secretion.



#### **Carrier molecules**

- Drugs bind to such molecules to alter their transport ability.
- Responsible for transport of ions and small organic molecules between intracellular compartments, through cell membranes or in extracellular fluids.
- o e.g. Na pump (Na+/K+ ATPase) blocked by digoxin.
- o e.g. dopamine transporter blocked by cocaine.

#### **Carrier molecules**

#### Digoxin:

blocks Na efflux via **Na+/K+ pump** or **sodium- potassium pump (Na+/K+-ATPase**); used in the treatment of heart failure.

#### **Cocaine:**

- blocks transport or reuptake of (<u>catecholamines</u>) <u>mainly dopamine</u>) at synaptic cleft.
- The dopamine transporter can no longer perform its reuptake function, and thus <u>dopamine</u> accumulates in the <u>synaptic cleft</u> producing euphoria.







**REGULATORY** 




**Digoxin blocks eff** 



### Effect of cocaine






#### Structural proteins

e.g. Tubulin is target for drugs as anticancer drugs and antigout drugs.

**Tubulin** is required for microtubules formation (cytoskeleton).




#### Structural proteins

#### **Vincristine**

Anticancer that kills cancerous cells by inhibiting microtubule formation and cell division.

#### Colchicine

- used in treatment of gout
- binds to tubulin and inhibits microtubule formation, preventing neutrophil motility and decreasing inflammation



# What are the binding Forces between drugs and receptors?

- Ionic bond.
- Van-Dar-Waal.
- Hydrogen bond.
- Covalent bond.

#### **Affinity**

Ability of a drug to combine with the receptor.

#### **Efficacy (Intrinsic Activity)**

- Capacity of a drug receptor complex (D-R) to produce an action.
- is the maximal response produced by a drug (E max).

#### **Agonist**

is a drug that combines with receptor and elicit a response (has affinity and efficacy).

e.g. acetylcholine (Ach) acts upon muscarinic receptors.

#### **Antagonist**

- is a drug that combines with a receptor without producing responses.
- It blocks the action of the agonist.
- It has affinity but no efficacy or zero efficacy.
- e.g. atropine block the action of Ach on muscarinic receptors.
- It has similar chemical structure to an agonist.

### **Agonist and Antagonist**



#### **Agonist**

Full agonist.

Partial agonist.

#### **Full Agonist**

A drug that combines with its specific receptor to produce maximal effect by increasing its concentration (affinity & high efficacy).


e.g. acetylcholine (Ach).

#### **Partial Agonist**

combines with its receptor & evokes a response (submaximal effect) regardless of its concentration (affinity & partial efficacy).

- e.g. pindolol
- a beta blocker which is a partial agonist, produces less decrease in heart rate than pure antagonists such as propranolol.

Partial Agonist: Even though the drugs may combine with the same number of receptors, the magnitude they can produce may differ



#### **TERMS DEFINITIONS**

**Affinity** is the capacity of a drug to form a complex with the receptor(DR complex)

**Efficacy**(Intrinsic activity) the ability of the drug once bound to the receptor to trigger response

The value of intrinsic activity ranges from 0 to 1

#### **TERMS DEFINITIONS**

Full agonist having a full affinity to the receptor and a maximal intrinsic activity (1) e.g. acetylcholine

Partial agonist having a full affinity to the receptor but with low intrinsic activity (<1) e.g. pindolol

Antagonist having full affinity to the receptor but no intrinsic activity(0) e.g. atropine



# PHARMACQLQGY